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Abstract
Objective: The objective of this selective EBM review is to determine whether or not Tesamorelin is a
safe and effective drug to treat lipodystrophy in HIV patients.
Study Design: Review of three English language primary randomized controlled trials
published between 2005-2010.
Data Sources: Randomized, placebo-controlled, double-blind clinical trials comparing Tesamorelin to
a visually matched placebo were found using PubMed.
Outcome(s) Measured: Each of the three clinical trials assessed the improvement of lipodystrophy
(accumulation of visceral adipose tissue) in HIV patients. In addition, they noted how the improvement
in lipodystrophy would impact patient's self body image and quality of life. Prior to the study, all
patients received a CT scan in order to get a visceral adipose tissue baseline, this allowed researchers to
note patient's percent change from baseline. Furthermore, patients also completed a self-perceived body
image questionnaire. Patients rated their “belly size” comparing their current appearance to their
perceived healthy look with scores from -100 (much thinner) to +100 (much bigger). Similarly, they
rated their “belly image distress” from 0 (extremely upsetting and distressing) to 100 (extremely
encouraging); and “belly profile” by choosing from six silhouettes scored from 0 (normal) to 5 (very
dysmorphic).
Results: Three randomized-controlled trials were included in this review. Results from each study
reveals that Tesamorelin (2 mg) is a safe and effective drug to treat lipodystrophy in HIV patients.
Similarly, patient's self body image and quality of life also improved due to the reduction in their
visceral adipose tissue. Although all three trials reported similar adverse events, for two of the trials,
headache was the most common; while injection site erythema was the most common for the other
trial.
Conclusion: The three randomized-controlled trials have proven that Tesamorelin is a safe and effective
treatment for lipodystrophy in HIV patients. It is because of these clinical trials that Tesamorelin was
approved by the FDA on November 10, 2010 and it is currently the only alternative treatment for
lipodystrophy in HIV patients besides surgery or diet and exercise.
Key Words: Tesamorelin; growth hormone releasing hormone; HIV; lipodystrophy; abdominal fat
accumulation
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INTRODUCTION
Human Immunodeficiency Virus (HIV) is a continually growing pandemic that affects
approximately 33.3 million people worldwide. HIV can affect people of all ages and is responsible for
about 1.8 million deaths annually. HIV is a retrovirus that can be acquired in a number of different
ways which include: sexual contact (vaginal, anal, or oral), intravenous drug use, tattoos, accidental
needle sticks in the healthcare setting, or from mother to child via pregnancy and childbirth (vertical
transmission). Once a person develops HIV, it can be up to 10 years or more before a person develops
Acquired Immune Deficiency Syndrome (AIDS). The development of AIDS (when the CD4 count is
less than 200) makes a person more likely to develop various opportunistic infections, dementia,
cardiovascular disease, diabetes, and various cancers. Ultimately, patients do not die of AIDS but they
instead die of the complications associated with having AIDS.1
Unfortunately, there is no cure for HIV; however, there are several treatment options available
to manage this disease and slow down the progression to AIDS. The most common regimen used to
manage HIV is HAART (highly active antiretroviral therapy) which generally includes a combination
of three drugs. The drug classes that may be included in the HAART combination are nucleoside or
non-nucleoside reverse transcriptase inhibitors (NRTI or NNRTI), protease inhibitors (PI), entry
inhibitors (includes fusion inhibitors), and integrase inhibitors. The average monthly cost of HAART
ranges between $2,100-4,700. Although these medications are extremely effective (especially when
used in combination), they have a lot of adverse side effects. The most common adverse side effect is
lipodystrophy and it is estimated that 14-40% of HIV patients on HAART will develop this. Of the
medications included in the HAART cocktail, it has been proven that protease inhibitors put patients at
greatest risk for developing lipodystrophy.2
Since the prevalence of lipodystrophy varies, it is not known how many healthcare visits occur
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each year due to this problem. It is well known that patients who develop lipodystrophy are at increased
risk for developing new onset hyperglycemia (5%), hypertriglyceridemia (19%), and
hypercholesterolemia (24%). Furthermore, it is known that hyperlipidemia, insulin resistance,
hyperinsulinemia, and hyperglycemia are features associated with HIV lipodystrophy which can
consequently put HIV patients at risk for developing atherosclerosis and diabetes.2
Since lipodystrophy is a continually growing problem in the HIV community, there was a need
to develop a better treatment method for this condition. Prior to the development of Tesamorelin
(Egrifta), the only available treatment options were surgery and diet and exercise.2 Surgical options
included: liposuction and lipectomy which can cost about $2884 nationally on average (not including
anesthesia or facility fees); however, re-occurrence was very common. With diet and exercise, no
specific regimen exists; however, adequate nutrition and exercise has shown modest improvement in
these patients. With the above being said, Tesamorelin is being proposed as a more effective treatment
option since the re-occurrence rate of the above treatment methods are rather high. Tesamorelin is to be
administered as a 2mg subcutaneous injection once a day. Since the approval of Tesamorelin, the latest
reported cost of Tesamorelin is approximately $2356.80 per month.3
OBJECTIVE
The objective of this selective EBM review is to determine whether or not Tesamorelin is a safe
and effective drug to treat lipodystrophy in HIV patients.
METHODS
All three clinical trials utilized for this review were selected because their population group
included male and female HIV patients with lipodystrophy who were over the age of 18 years old. The
intervention used for these HIV patients was 2 mg of Tesamorelin (subcutaneous injection in the
abdomen) and the comparison group of HIV patients were treated with a visually matched placebo.
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Outcomes measured included how effective Tesamorelin was overall at improving body
composition (reduction of visceral adipose tissue) and improving self body image as well as quality of
life; which are patient oriented evidence that matters. The amount of visceral adipose tissue was
predetermined by a CT scan and the improvement was based on a change from the baseline amount.
The remaining outcomes were based on improvement in questionnaire scores on self body image and
quality of life. The types of studies that were included are randomized-controlled trials; one of the
studies was double-blind and placebo-controlled while the other two studies were only doubleblinded.4,5,6
Information obtained for this review was found on PubMed using the following key words:
Tesamorelin, growth hormone releasing hormone, HIV, lipodystrophy, and abdominal fat accumulation.
All articles were published in the English language in peer-reviewed journals that were published
between the years 2005-2010. All of the articles were selected based on their relevance and importance
of outcomes to the patient. The three trials were included in this review because they met the following
inclusion criteria: randomized-controlled trials published after 1996, articles that included patient
oriented evidence that matters, and studies that were double-blinded. Other studies were excluded
because they were not randomized-controlled trials and they did not include the selected patient
population. The statistics in this review were reported using p-value, numbers needed to treat (NNT),
relative benefit increase (RBI), and absolute benefit increase (ABI).
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Table 1. Demographics of included studies. I was unable to include all of the inclusion &
exclusion criteria because the list is very long so I included the most common.
Study

Type

# of pts

Age

Inclusion
Criteria
Men & women
age 18-65 w/
HIV
Lipodystrophy
(WC ≥ 95 cm
for men & ≥ 94
cm for women
or a WTH ratio
≥ 0.94 cm for
men & ≥ 0.88
for women).

Exclusion
Criteria
-Pts with a
BMI ≤ 20
kg/m2
-Pts
receiving
estrogen
w/in 6
months of
the study
-Pts w/ a
clinical
history of
pituitary
disease

W/D

Intervention

Faultz
Article4,
2010

RCT
(doubleblind
study)

404

47.7 + 7.5

31

Randomized to
receive 2 mg
of SQ
Tesamorelin or
Placebo

Faultz
Article5,
2007

RCT
(doubleblind
study)

412

47.3 + 7.3

Men & women
age 18-65 w/
HIV
Lipodystrophy
(WC ≥ 95 cm
for men & ≥ 94
cm for women
or a WTH ratio
≥ 0.94 cm for
men & ≥ 0.88
for women).

-Pts
receiving
estrogen
w/in 6
months of
the study
-Pts w/ a
clinical
history of
pituitary
disease

32

Randomized to
receive 2 mg
of SQ
Tesamorelin or
Placebo

Faultz
Article6,
2005

RCT
(doubleblind,
placebo
controlled)

61

44.6

Men & women
age 18-65 w/
HIV
Lipodystrophy
(WC ≥ 95 cm
for men & ≥ 94
cm for women
or a WTH ratio
≥ 0.94 cm for
men & ≥ 0.88
for women).

-Pts with a
BMI ≤ 20
kg/m2
-Pts w/ a
prior
history of
DM Type I
-Pts w/
prior use of
GH or GHrelated
products
w/in 6
months of
the study

10

Randomized to
receive 2 mg
of SQ
Tesamorelin or
Placebo.
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OUTCOMES MEASURED
Each of the three clinical trials assessed the overall improvement of body composition (visceral
adipose tissue) while noting how this improvement also impacted patient's self body image and quality
of life. All of the above measured outcomes are patient oriented evidence that matters. Prior to the
study, all participants had their amount of visceral adipose tissue predetermined by a CT scan and
improvements were noted in the amount of change from baseline. The remaining outcomes were based
on improvement in baseline questionnaire scores on self body image and quality of life. The selfperceived body image questionnaire had patients rate their “belly size” comparing their current
appearance to their perceived healthy look with scores from -100 (much thinner) to +100 (much
bigger). Similarly, the questionnaire had patients rate their “belly image distress” from 0 (extremely
upsetting and distressing) to 100 (extremely encouraging); and “belly profile” by choosing from six
silhouettes scored from 0 (normal) to 5 (very dysmorphic). 4,5
RESULTS
The results of all three clinical trials evaluated were presented as dichotomous data in
order to evaluate the improvement of lipodystrophy in HIV patients.
Faultz et al (2010) found that visceral adipose tissue decreased by -10.9% (-21 cm2) in the
Tesamorelin group versus only a -0.6% (-1 cm2) in the placebo group. This data demonstrated a
17.17% RBI and a -0.103% ABI when comparing Tesamorelin to the visually-matched placebo. NNT
for this study was found to be -10 with a p-value of <0.001 and a 95% CI of (-28 to -11) (Table 2). A
negative NNT value in this study indicated that for every ten patients who were given Tesamorelin,
there would be one fewer patient who would have a reduction in visceral adipose tissue when compared
to the placebo. The p-value of <0.001 indicates that this test is statistically significant and we are 95%

confident that the true NNT for the population lies between the interval -28 and -11.4
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Faultz et al (20007) also compared Tesamorelin to a visually matched placebo. This study found
that patients who received Tesamorelin had a decrease of 27.8 cm2 in visceral adipose tissue while
patients who received the placebo had an increase in visceral adipose tissue of 5.1 cm2 . The calculated
RBI was 2.04% and the ABI was 0.102%. Moreover, the NNT was calculated to be 10 with a p-value
of <0.001 and a 95% CI of (-40.7 to -25.0) (Table 2). A positive NNT value in this study indicates that
ten patients must be treated with Tesamorelin in order for one additional patient to benefit from
Tesamorelin when compared to the placebo group. The p-value of <0.001 indicates that this test is
statistically significant and we are 95% confident that the true NNT for the population lies between the
interval -40.7 and -25.0.5
The study performed by Faultz et al (2005) also compared Tesamorelin to a visually-matched
placebo. This study showed that patients who received Tesamorelin had a decrease in visceral adipose
tissue of -15.7% while the placebo only had a decrease of -5.4%. The RBI was calculated to be 1.91
and the ABI was -0.103. Furthermore, the NNT was calculated to be -10 with a p-value=0.03 (Table 2).
No confidence interval was provided by this study. A negative NNT value in this study indicated that
for every ten patients who were given Tesamorelin, there would be one fewer patient who would have a
reduction in visceral adipose tissue when compared to the placebo. The p-value=0.03 indicates that this
test is not statistically significant.6
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Table 2. Efficacy of Tesamorelin on Improving Lipodystrophy (Overall Body Composition)
Study
Relative benefit
Absolute
Number needed p-value
95%
increase (RBI) benefit increase to treat (NNT)
Confidence
(ABI)
Interval (CI)
Faultz Article1, 17.17
2010

-0.103

-10

p< 0.001

95% CI: (-28 to
-11)

Faultz Article2, 2.04
2007

0.102

10

p<0.001

95% CI: (-40.7
to -25.0)

Faultz Article3, 1.91
2005

-0.103

-10

p=0.03

NR

In addition to the above, two of the trials noted how reducing lipodystrophy would impact
patient's self body image while the other study noted how it impacted patient's quality of life. In terms
of self body image, patients were given a questionnaire prior to the study and they were asked to rate
their body image distress (0 to 100), belly size (-100 to 100), and belly profile (0 to 5). Table 3a
represents that values of improvement in these three areas for Faultz et al (2010) and Faultz et al
(2007). The baseline questionnaire scores were not reported in either of the studies and all of these
values represent an overall change from the baseline.4,5
Faultz et al (2010) showed an improvement of 8.4 + 29.0 in the Tesamorelin group versus only
5.2 + 26.6 in the placebo group for belly image distress and the reported p-value was 0.02. Moreover,
the Tesamorelin group demonstrated a 14.8 + 27.8 improvement in belly size while patients in the
placebo group had a 11.7 + 25.2 with a p-value of 0.21. Lastly, belly profile seemed to improve in the
Tesamorelin group with -0.5 + 1.3 versus -0.3 + 1.0 in the placebo group with a p-value of 0.08. All of
the reported p-values for improving self body image for this study were deemed significant except for
the p-value that represents belly size (See table 3a).4
Faultz et al (2007) showed similar improvements to that of Faultz et al (2010) in all areas. For
belly image distress, the reported improvements were 11.6 + 26.9 and 6.2 + 25.8 for Tesamorelin and

placebo respectively; with a p-value of 0.03. In terms of belly size, the reported improvement scores
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were 35.1 + 55.0 and 35.4 + 55.0 for Tesamorelin and placebo respectively; with a reported p-value of
0.70. Furthermore, the study reported the improvement scores for belly profile as 0.67 + 1.25 and 0.34
+ 1.25 for Tesamorelin and placebo respectively with a p-value of 0.03. All of the reported p-values for
improving self body image in this study were concluded to be significant except for the p-value that
represents belly size (See table 3a).5
Table 3b represents the improvements in quality of life as reported in Faultz et al (2005). The
quality of life element which improved the most was social well being. The baseline score in the
Tesamorelin group was 3.00 with a change of -0.34 versus a baseline score of 2.80 with a change of
-0.07 in the placebo group. The reported p-value was 0.05 which indicates that this test is statistically
significant.6
Table 3a. Efficacy of Tesamorelin on Improving Body Image
Study
Belly Image Distress
Belly Size

Belly Profile

Faultz Article1, Tesamorelin: 8.4 + 29.0 Tesamorelin: 14.8 +
2010
Placebo: 5.2 + 26.6
27.8
p-value=0.02
Placebo: 11.7 + 25.2
p-value=0.21

Tesamorelin: -0.5 + 1.3
Placebo: -0.3 + 1.0
p-value=0.08

Faultz Article2, Tesamorelin: 11.6 +
2007
26.9
Placebo: 6.2 + 25.8
p-value=0.03

Tesamorelin: 0.67 + 1.25
Placebo: 0.34 + 1.25
p-value= 0.03

Tesamorelin: 35.1 +
55.0
Placebo: 35.4 + 55.0
p-value=0.70

Table 3b. Efficacy of Tesamorelin on Improving Quality of Life (Social Well Being)
Study
Tesamorelin
Tesamorelin
Placebo
Placebo
p-value
Baseline
Change
Baseline
Change
Faultz Article3, 3.00
2005

-0.34

2.80

-0.07

0.05

Lastly, each of the three trials reported and discussed any adverse events that occurred during
the study. For two of the trials, the most common reported adverse event was headache which is seen in

table 4. In Faultz et al (2007), RRI was -0.115%, ARI was -0.021%, and NNH was -48 with a p-value
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of 0.58 which means the test is statistically insignificant. A negative NNH in this case means that for
every forty-eight patients, one more patient will report the adverse effect of headache if they received
Tesamorelin (See table 4).5 Similarly, with Faultz et al (2005), RRI was 1.070%, ARI was 0.150%, and
NNH was 7. No p-value was reported for this study. A positive NNH for this study means seven
patients must be treated with Tesamorelin for one person to develop a headache. (See table 4).6
In Faultz et al (2010), the most common reported adverse event was injection site erythema
which is seen in table 4. The RRI was 1.940%, the ARI was 0.093%, and NNH was 11 with a p-value
of 0.006. A positive NNH in this case means that 11 patients must be treated with Tesamorelin for one
person to experience erythema at the injection site. The p-value of 0.006 means that the test is
statistically significant (See Table 4). 4
Table 4. Adverse Events: Headache and Injection Site Erythema
Study

Adverse Event

Relative risk
increase (RRI)

Absolute risk Number needed p-value
increase (ARI) to harm (NNH)

Faultz Article2, Headache
2007

-0.115

-0.021

-48

p=0.58

Faultz Article3, Headache
2005

1.070

0.150

7

NR

Faultz Article1, Injection Site
2010
Erythema

1.940

0.093

11

p=0.006

DISCUSSION
Throughout all three clinical trials, Tesamorelin (2 mg) was proven to be an effective drug to
treat lipodystrophy in HIV patients; however, Faultz at el (2005) was limited in that the sample size
only included 61 patients and the study was only conducted over a 12 weeks period compared to the
other studies which had a larger sample size and a longer duration.4,5,6 Since it's FDA approval,

Tesamorelin is only indicated to treat lipodystrophy in HIV patients. Tesamorelin is an accepted
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treatment option in the United States; however, several steps must be taken before a patient can be
prescribed this medication. If a clinician would like their patient to take Tesamorelin, they must fill out
a Statement of Medical Necessity (SMN) that is signed by the clinician and patient. This form must
then be faxed to the AXIS Center which is the center that provides patient information and education
about Tesamorelin. The AXIS Center offers reimbursement programs, in-home or in-office training on
how to properly use Tesamorelin; as well as 24 hour customer support. A clinician can only get the
SMN forms from EMD Serono (the company that makes Tesamorelin) or the AXIS center.7
Another problem that clinicians may run into is the cost of Tesamorelin. As stated earlier, the
cost is about $2356.80 per month which may not be covered by the patient's insurance; however there
are some solutions available to address this problem. One solution is the Co-pay assistance program.
This program was designed for commercially insured patients with a prescription drug benefit that
covers Tesamorelin (Egrifta). And this program will cover up to $2,400 of patients' out of pocket cost
over a 12-month period. Patients must use the card for the first time in 2011 and can off-set up to $200
of their copay or coinsurance for up to 12 uses prior to 12/31/12. Unfortunately, patients with Medicare
or Medicaid or patients who live in Massachusetts may not use this program. Another solution is
Patient Assisted Program (PAP) which offers free Tesamorelin to eligible patients who are under or
uninsured. In order for patients to qualify for PAP, they must meet the following criteria: household
income that does not exceed 600% of the Federal Poverty Level (FPL), must be diagnosed with HIV,
and must be a resident of the United States. PAP is only available on a yearly basis and patients must
reapply every year to receive this benefit.7
In addition to being an effective drug, Tesamorelin also proved to be a relatively safe drug. The
most common side effect reported in two of the articles was headache while the other article reported

injection site erythema (reported in tables above). Moreover, there are some contraindications for the
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use of Tesamorelin which includes pregnancy (Tesamorelin is a Category X), known hypersensitivity to
Tesamorelin and/or Mannitol, active malignancy (either newly diagnosed or recurrent), and disruption
of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery,
head trauma, or head irradiation.7
CONCLUSION
Tesamorelin, a growth hormone releasing factor, was proven to be a safe and effective treatment
for lipodystrophy in HIV patients. In addition, Tesamorelin overall demonstrated low numbers of
treatment induced adverse events which further proves that it is a safe and effective drug. Due to these
clinical trials, the FDA officially approved Tesamorelin on November 10, 2010; making it the first and
only approved drug to treat lipodystrophy in HIV patients. Although the methods used in these trials
were sufficient and proved that Tesamorelin can improve lipodystrophy by decreasing visceral adipose
tissue; however these trials failed to demonstrate how these changes benefit patients long term with
their cardiovascular health. Therefore, a future study is warranted to evaluate how reducing visceral
adipose tissue improves cardiovascular health in HIV patients. Furthermore, due to the success of this
drug for HIV patients, Tesamorelin is currently being studied for use in healthy adults to reduce
visceral adipose tissue and to improve mild cognitive impairment.
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